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Medicine and Surgery, Federico II University. PAbstract Background and aims: Incretin hormones glucagon-like peptide (GLP)-1 and glucose-
dependent insulinotropic polypeptide (GIP) are affected early on in the pathogenesis of meta-
bolic syndrome and type 2 diabetes. Epidemiologic studies consistently link high fructose con-
sumption to insulin resistance but whether fructose consumption impairs the incretin
response remains unknown.
Methods and results: As many as 66 obese (BMI 26e40 kg/m2) male subjects consumed fructose-
sweetened beverages containing 75 g fructose/day for 12 weeks while continuing their usual life-
style. Glucose, insulin, GLP-1 and GIP were measured during oral glucose tolerance test (OGTT)
and triglycerides (TG), GLP-1, GIP and PYY during a mixed meal test before and after fructose
intervention. Fructose intervention did not worsen glucose and insulin responses during OGTT,
and GLP-1 and GIP responses during OGTT and fat-rich meal were unchanged. Postprandial TG
response increased significantly, p Z 0.004, and we observed small but significant increases in
weight and liver fat content, but not in visceral or subcutaneous fat depots. However, even the
subgroups who gained weight or liver fat during fructose intervention did not worsen their
glucose, insulin, GLP-1 or PYY responses. A minor increase in GIP response during OGTT occurred
in subjects who gained liver fat (p Z 0.049).
Conclusion: In obese males with features of metabolic syndrome, 12 weeks fructose intervention
75 g/day did not change glucose, insulin, GLP-1 or GIP responses during OGTT or GLP-1, GIP ormental curve; AUC, area under curve; GIP, glucose-dependent insulinotropic polypeptide; GLP-1,
nsity lipoproteins; LDL, low density lipoproteins; OGTT, oral glucose tolerance test; PYY, peptide YY;
rams Unit, Diabetes and Obesity, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.
s.fi (N. Matikainen).
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Fructose intervention and incretins 535PYY responses during a mixed meal. Therefore, fructose intake, even accompanied with mild
weight gain, increases in liver fat and worsening of postprandial TG profile, does not impair
glucose tolerance or gut incretin response to oral glucose or mixed meal challenge.
ª 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. All rights reserved.Introduction
An increase in the prevalence in obesity and diabetes
closely parallels the dramatic rise in sugar, especially
fructose, intake due to consumption of sugar-sweetened
beverages (SSBs) that accounts for nearly one-half of all
added sugar intake in the U.S. [1]. Nowadays, fructose is a
major sweetener in Western diets [2]. In the U.S., 50% of
population consumes SSBs daily, and 25% obtains at least
200 kcal from these beverages [1].
The relationship between SSB and cardiometabolic
diseases seen in epidemiological studies reflects potential
combined effects of fructose and glucose or unique effects
of fructose alone. The current data suggest a causative
relationship between the intake of sweeteners, particu-
larly fructose, and the increased prevalence of non-
alcoholic fatty liver disease and dyslipidemia [1,3,4],
especially postprandial plasma triglycerides (TG) [5].
Whether fructose consumption directly causes insulin
resistance is much debated, and despite epidemiological
evidence suggesting a link, data from intervention studies
are inconsistent [4,6e13]. However, most studies included
relatively small numbers of participants, a short inter-
vention period or used only fasting insulin as a marker for
insulin sensitivity. A 3-week consumption of fructose in 9
normal-weight young males impaired insulin sensitivity,
measured as suppression of hepatic glucose production
during a clamp, but did not change fasting insulin or
glucose levels [13]. Insulin sensitivity, assessed from fast-
ing insulin levels and deuterated glucose disposal,
decreased after a 10-week fructose consumption in over-
weight/obese humans [12]. Studies assessing the effect of
hypercaloric fructose consumption with respect to both
liver fat and insulin resistance have mostly reported no
change in insulin sensitivity, with varying effects on liver
fat [6e10]. One study with 6e7 days intervention reported
worsened insulin resistance together with increased liver
fat [11].
Gut incretins, mainly glucagon-like peptide (GLP)-1 and
glucose-dependent insulinotropic polypeptide (GIP),
mediate the insulinotropic response to intraluminal nu-
trients [14]. Defects in either secretion or insulinotropic
actions of GLP-1 and GIP are early signs of acquired insulin
resistance characterizing the metabolic syndrome [5,16].
Data on whether a single dose of fructose stimulates GLP-1
secretion in humans are inconsistent [17e19], whereas GIP
secretion remains unaffected [17e19]. However, no data
exists on the effect of longer fructose intervention on GLP-
1 and GIP responses to nutritional stimuli.Here, we test the hypothesis whether worsening of
glycemic control induced by fructose consumption (75 g/
day for 12 weeks served as a lemonade together with
habitual ad libitum diet) may involve a gut incretin-
dependent mechanism. Therefore, we studied the re-
sponses of GLP-1 and GIP in the fasting state and following
a standard oral glucose tolerance test (OGTT) and the more
physiological mixed meal test before and after fructose
intervention in overweight male subjects who have high
risk for future diabetes.
Methods
Study cohort
We recruited 82 obese healthy men to the Fructose inter-
vention study (Clinical Trials NCT01445730) at four centers
including in Quebec, Canada; Helsinki, Finland; Naples,
Italy; and Gothenburg, Sweden. Two subjects discontinued
the intervention study: one due to skin rash which was
considered as possible allergic reaction to flavoring. The
rash disappeared after the discontinuation. The other
subject discontinued the study in response to his dentist’s
advice. In addition, the data from magnetic resonance
examinations at baseline or after the fructose intervention
were not sufficient from 9 subjects to allow the analyses of
different fat depots and the incretin measurements after
OGTT or mixed meal were lacking from 5 subjects for
technical reasons. Thus, 66 subjects completed the full
study protocol except for one subject, who lacked insulin
measurements during OGTT. Subjects were recruited via
newspaper advertisements. Inclusion criteria were the
following; men with large waist circumference (>96 cm),
body mass index (BMI) between 27 and 40 kg/m [2], and
stable weight (3 kg) for at least the last 3 months, LDL-
C < 4.5 mmol/l and TG < 5.5 mmol/l. Exclusion criteria
were: age <20 years or >65 years, BMI or lipid levels
outside the inclusion ranges, smoking, alcohol consump-
tion over 2 doses/day (i.e., 20 g pure alcohol), type 2 dia-
betes, cardiovascular disease, hormonal therapy, hepatic
and renal diseases, gastroenterological, thyroid or hema-
tological abnormalities, and any chronic disease requiring
medication except for controlled hypertension. None of
the subjects used any medication or hormones known to
influence glucose or lipoprotein metabolism. The study
design was approved by the local Ethics committees and
each subject gave written informed consent before
participation in the study. All the samples were collected
in accordance with the Declaration of Helsinki.
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Each subject underwent a 12-week fructose intervention
period, during which they consumed 75 g of fructose
daily. Fructose was administered as three daily 330 ml
bottles equaling 990 ml and 303 kcal per day. The
carbonated beverages were prepared as 7.6% (w/w) so-
lutions and flavored with lemon aroma (specially pro-
duced for this study by Nokian Panimo Oy, Finland).
Subjects were instructed to consume the beverages
together with the three main meals while continuing
their habitual ad libitum diet and physical activity during
the intervention. The fructose-sweetened beverage was
well tolerated. Each subject kept a 3-day food record (2
work days and 1 day off) before the fructose intervention
period and again within 2 weeks before completing the
intervention period. A qualified nutritionist gave detailed
verbal and written instructions for filling in the food re-
cords and contacted the participants every 1e2 weeks
to assure compliance with fructose intervention and
lifestyle.
Study design
The subjects participated in 3 separate study visits within
2 weeks before the fructose intervention period: 1) oral
glucose tolerance test (OGTT), 2) mixed meal test, and 3)
magnetic resonance imaging. These visits were repeated
within 2 weeks before completing the 12-week fructose
intervention period. The OGTT (75 g) was performed after
an overnight fast. Subjects consumed 75 g of glucose and
blood sampling was done before and at 5, 10 and 30 min,
and 1, 1.5, 2, 3 and 4 h. The standardized mixed meal test
was performed at each center after an overnight fast. The
subjects received a mixed meal test consisting of bread,
butter, cheese, ham, boiled eggs, fresh red pepper, low fat
(1%) milk, orange juice and tea or coffee (63 g carbohy-
drates, 56 g fat and 40 g protein). The fat-rich meal con-
tained 927 kcal. Blood samples were drawn before and at
0.5, 1, 2, 3, 4, 6, and 8 h after the meal. During the test, only
water was allowed ad libitum and the subjects remained
physically inactive. The participants abstained from
alcohol and physical exercise for two days before each
examination.
Determination of liver, subcutaneous and visceral fat
depots
Proton magnetic resonance spectroscopy was performed
with a 1.5 T whole-body device to determine liver fat
content [20]. A standardized protocol was used at all
centers, and all analyses of the imaging results were per-
formed by one person (AH). Subjects were advised to fast
for 4 h before imaging.
Biochemical analyses
TG and cholesterol concentrations in total plasma were
analyzed by automated enzymatic methods using theKonelab 60i analyzer (Thermo Fisher Scientific Inc., Espoo,
Finland). Concentrations of glucose (hexokinase method,
Roche Diagnostic Gluco-quant, Mannheim, Germany). In-
sulin (electrochemiluminescence with Roche sandwich
immunoassay on a Cobas autoanalyzer) was measured
during OGTT.
GLP-1 and GIP plasma concentrations were measured
after ethanol extraction (70% vol/vol, final concentration)
using C-terminally directed assays, which detect both the
intact peptide and the primary (N-terminally truncated)
metabolite; such assays therefore can be designated as
“total”, and the results can be interpreted to reflect the rate
of secretion [21]. For GIP [22], we used antiserum code #
80867, which reacts fully with GIP 3e42, but not with GIP
8000, whose chemical nature and relationship to GIP
secretion is uncertain. Plasma concentrations of GLP-1
were measured [23] using antiserum code no. 89390,
which is specific for the amidated C-terminus of GLP-1.
PYY concentrations were measured during mixed meal
(Fasting and 4 h) with Elisa method (Merck, Darmstadt,
Germany).Statistical analyses and calculations
Statistical analyses were performed using IBM SPSS Sta-
tistics (Version 22, NY, USA). Data are presented as
mean  SEM or standard deviation and range. HOMA-IR
indices were calculated as described previously [24]. A
web-based calculator was used to calculate Matsuda Index
and Insulinogenic Index during OGTT (http://mmatsuda.
diabetes-smc.jp/MIndexsi.html). Comparisons between
before and after fructose intervention were evaluated with
paired nonparametric tests (the Wilcoxon Matched-Pair
Signed-Rank test to continuous data when comparing
two specified variables and Friedman’s 2-Way ANOVA by
Ranks to continuous data when comparing more than 2
specified variables). In case of significant differences in 2-
Way ANOVA, post hoc analysis was done with Scheffe’s
method. The area under curve (AUC) and incremental AUC
(i.e., the AUC above the fasting concentration; AUIC) for
postprandial variables were calculated according to the
trapezoid rule. Correlations were calculated using Spear-
man’s rank test. A p value < 0.05 was considered statisti-
cally significant.Results
Baseline characteristics
The study subjects were on average 48 years old and had a
BMI of 30.6 kg/m2. Their characteristics are summarized in
Table 1. Before the OGTT or mixed meal, fasting concen-
trations of glucose, insulin, GLP-1 and GIP were essentially
similar. There were no correlations between fasting con-
centrations of GLP-1 or GIP with BMI, liver fat, subcu-
taneous or visceral fat nor with concentrations of fasting
glucose or insulin. Only fasting GLP-1 correlated with
HOMA-IR (r Z 0.245, p Z 0.049).
Table 1 Subject characteristics before and after the fructose intervention period. Data are mean  standard error of mean and range.
Before After p-value
Mean SEM Range Mean SEM Range
Age, y 49.0 1.2 21e65
BMI, kg/m2 30.6 0.3 26.5e38.2
Weight, kg 99.2 1.4 65.2e135 100.0 1.5 66.8e136 0.002
fP-Glucose, mmol/l 5.45 0.06 4.50e6.50 5.54 0.07 4.30e7.00 0.090
fP-Insulin, pmol/l 98.3 7.0 19.0e293.0 98.2 7.4 13.0e358.0 0.987
HOMA-IR 4.0 0.3 0.9e13.7 4.1 0.3 0.5e15.1 0.710
HOMA-S 143.2 9.2 20.4e408.4 135.7 9.4 21.3e453.6 0.216
Matsuda Index 3.43 0.23 0.85e9.42 3.61 0.30 0.70e13.55 0.961
Insulinogenic Index 1.25 0.12 1.28 to 4.72 1.25 0.12 0.02 to 7.09 0.645
fP-GLP-1 (OGTT), pmol/l 13.8 0.7 4.0e31.0 13.7 0.6 6.0e29.0 0.767
fP-GLP-1 (mixed meal), pmol/l 13.5 0.7 3.0e37.0 13.6 0.7 4.0e31.0 0.051
fP-GIP (OGTT), pmol/l 13.9 2.3 3.0e154.0 12.3 0.6 3.0e27.0 0.322
fP-GIP (mixed meal), pmol/l 11.1 0.6 3.0e29.0 12.2 0.7 2.0e27.0 0.070
fS-TG, mmol/l 1.56 0.11 0.34e4.52 1.66 0.11 0.46e4.25 0.032
Liver fat, % 6.9 0.8 0.3e24.8 7.5 0.8 0.6e27.7 0.021
Visceral fat, cm3 2487 117 538e5434 2513 111 612e5198 0.621
Subcutaneous fat, cm3 4223 169 1820e8491 4243 176 1832e8389 0.131
fP-PYY, pg/ml 107.7 7.8 28.3e369.2 100.1 6.4 32.8e247.3 0.220
P-PYY 4 h, pg/ml 164.6 9.4 31.1e496.9 165.5 8.5 54.1e384.7 0.856
Fructose intervention and incretins 537Fructose intervention does not modify indexes of insulin
sensitivity or secretion or responses of glucose, insulin or
incretins during OGTT
During the standard OGTT, the responses (both AUC and
AUIC) of glucose, insulin, GLP-1 and GIP were essentially
similar before and after fructose intervention (Fig. 1). In
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Figure 1 Panel A. Responses of glucose, insulin, GLP-1 and GIP after OGTT b
Responses of triglycerides, GLP-1 and GIP after mixed meal test before
mean  SEM.Index or Disposition Index did not change significantly
during fructose intervention (Table 1).
Fasting or postprandial PYY concentrations are not
affected by fructose intervention
PYY concentrations rose similarly by 65 and 60%
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efore (solid line) and after fructose intervention (dashed line). Panel B.
(solid line) and after fructose intervention (dashed line). Data show
538 N. Matikainen et al.and after fructose intervention, respectively. The 12 weeks
fructose intervention did not have an impact on PYY levels.
The data are presented in Table 1.
Fructose intervention increases postprandial responses
of triglycerides but not that of incretins during mixed
meal
Fructose intervention increased fasting TG concentration
slightly but significantly (Table 1). The postprandial TG
responses differed before and after fructose intervention,
with the response of plasma TG being higher after fructose
intervention (Table 2). The difference was due to higher
plasma TG values at 0, 0.5, 1 and 2 h after the fructose
intervention (Table 1, Fig. 1). The AUC or AUIC responses of
GLP-1 and GIP during the mixed meal did not differ before
or after fructose intervention, but peak concentrations for
both GLP-1 and GIP occurred later during the mixed meal
(at 2 h) as compared to peak at 0.5 h during the OGTT.
Impact of fructose intervention on diet composition, body
weight, liver fat and fat depots
Based on 3-day food records, the subjects adjusted their
diets and the increase in energy intake during the fructose
intervention was small (only 58 kcal) and did not reach
statistical significance. Fructose intake at baseline was
14.5  1.0 g/day and increased to 85.7  0.8 g/day during
the fructose intervention. The proportion of energy from
total carbohydrates was higher, but that of sucrose, pro-
tein, total fat, and saturated and unsaturated fatty acids
was lower during the fructose intervention period. The
detailed intake of energy and macronutrients are shown in
Supplementary Table 2.Table 2 Glucose, insulin and incretin responses after OGTT and
incretin and TG responses after a mixed meal test. Areas under
curve (AUC) and areas under incremental curve (AUIC) are given
before and after 12 weeks fructose intervention. Data are
mean  standard error of mean. The given p-value shows differ-
ences between before and after fructose measurement (Wilcoxon
signed rank test).
Before After
Mean SEM Mean SEM p
OGTT
Glucose AUC, mmol/l h 1574 33 1583 34 0.740
Glucose AUIC, mmol/l h 266 28 254 26 0.496
Insulin AUC, pmol/l h 96,640 7896 101,409 8839 0.722
Insulin AUIC, pmol/l h 73,050 6987 77,849 7929 0.801
GLP-1 AUC, pmol/l h 4401 182 4405 139 0.535
GLP-1 AUIC, pmol/l h 1099 115 1110 113 0.587
GIP AUC, pmol/l h 7293 357 7611 372 0.067
GIP AUIC, pmol/l h 3955 455 4662 291 0.126
Mixed meal
TG AUC, mmol/l h 1128 73 1238 74 0.004
TG AUIC, mmol/l h 379 30 441 35 0.025
GLP-1 AUC, pmol/l h 8525 358 8321 326 0.522
GLP-1 AUIC, pmol/l h 3671 254 3418 305 0.305
GIP AUC, pmol/l h 20,848 1023 21,522 1144 0.387
GIP AUIC, pmol/l h 16,860 973 17,125 1065 0.814In general, 12 weeks fructose intervention increased the
weight slightly, but statistically significantly from 99.2 to
100.0 kg (p < 0.002). The relative increase of liver fat was
9.2% (absolute increase from 6.9% to 7.5%, p Z 0.021)
during fructose intervention. However, fructose interven-
tion did not change the subcutaneous (p Z 0.131) or
visceral (p Z 0.526) fat depots (Table 1).
Impact of weight and liver fat changes on incretin
response during fructose intervention
Because weight and liver fat changes are important de-
terminants of glycemic control, we divided the study
population to three subgroups according to 1) weight
change and 2) liver fat change. Weight groups were:
weight stable group (n Z 30) with 0e1 kg change, weight
gain group (n Z 27) with 1 kg increase and weight loss
group (n Z 9) with 1 kg decrease in body weight during
the fructose intervention. Liver fat groups were: Stable
liver fat group with no or minimal change from 3.7% to
4.1% (n Z 17), increased liver fat group with liver fat gain
from 8.7% to 11.3% (n Z 27) and reduced liver fat group
with decrease in liver fat from 7.1% to 5.4% (n Z 22).
In the whole study group, fructose intervention did not
alter any measurement of glucose metabolism but we wan-
ted to exclude the effect of weight on OGTT responses. We
therefore analyzed the weight stable, weight gain and
weight loss groups separately but the results remained un-
changed with no statistical difference between glucose, in-
sulinorGIPAUCorAIUCbeforevs. after fructose intervention
in any of the weight change groups (see Fig. 2 for AUC data).
Likewise, the incretin responses as well as PYY responses
during mixed meal test were similar before and after fruc-
tose in each weight group but the TG AUC was significantly
higher in the weight gain group (data not shown).
Because the liver fat content is closely linked to insulin
sensitivity and a predictor of diabetes, we wanted to
exclude the possibility that subjects with liver fat gain
respond to fructose intervention differently compared to
subjects who do not increase or even decreased liver fat
during fructose intervention. The metabolic characteristic
including liver fat changes are given in Supplementary
Table 1. These three groups did not show any statistically
difference in weight, fasting glucose, visceral fat, subcu-
taneous fat or fasting TG at baseline or after fructose
intervention. However, in the liver fat increase group,
fasting insulin and HOMA-IR were higher than in the other
two groups and these changes persisted during fructose
intervention. Despite the diverse liver fat responses and
5.9% difference in liver fat after the fructose intervention
between liver fat decrease and liver fat increase groups,
there were no differences in glucose, insulin or GLP-1 re-
sponses during OGTT, although the GIP AUC increased
slightly in the increased liver fat group (p Z 0.049, Fig. 3).
During mixed meal test there were no changes in 4 h PYY
concentrations or GLP-1 and GIP AUCs during fructose
intervention, but as expected the TG AUC increased, which
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p=0.049 
Figure 2 AUC responses of glucose, insulin, GLP-1 and GIP after OGTT by weight group. Weight stable n Z 30, weight gain n Z 27, weight loss
nZ 9. Data are mean  SEM. The given p-value shows differences between before and after fructose measurement, all other variables did not change
significantly (Wilcoxon signed rank test).
Fructose intervention and incretins 539Discussion
This is the first study to report the effect of fructose con-
sumption in obese non-diabetic males on incretin re-
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Figure 3 AUC responses of glucose, insulin, GLP-1 and GIP after OGTT by li
liver fat n Z 22. Data are mean  SEM. The given p-value shows differences
not change significantly (Wilcoxon signed rank test).that despite mild but significant weight and liver fat gain
accompanied with fasting and postprandial TG increase,
fructose consumption had no impact on either glycemic
control or GLP-1 and GIP responses. Furthermore, although
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ver fat group. Stable liver fat n Z 17, increased liver fat n Z 27, reduced
between before and after fructose measurement, all other variables did
540 N. Matikainen et al.TG profiles, this was not associated with worsening of
HOMA-IR, glucose tolerance during 4 h OGTT or GLP-1 or
GIP responses measured either during OGTT or mixed
meal. As expected, the energy intake was slightly hyper-
caloric during fructose intervention. However actual
change of caloric intake was not significant as the subjects
adjusted their caloric intake from other food and drinks
and also fasting and postprandial PYY concentrations
reflecting satiety remained stable. So our results suggest
that daily fructose intake of 75 g consumed with a close to
weight-maintaining diet does not in itself alter glycemia,
but has adverse effects on lipid metabolism.
Our study population was obese, with a large waist
circumference, and 41% had elevated screening TG con-
centrations, and as such, consisted of a high diabetes risk
population that should be more prone to develop acquired
insulin resistance. The present findings are in contradic-
tion with strong, positive epidemiologic associations re-
ported between fructose intake and components of the
metabolic syndrome, insulin resistance and diabetes
[1,25]. On the other hand, clinical trials have not been as
consistent. Although fructose consumption increases liver
fat, fasting TG, and systolic blood pressure and decreases
HDL [26], not all studies report impaired glycemic vari-
ables. A recent meta-analysis of 29 published studies
described effects of fructose in 1005 normal-weight and
overweight or obese non-diabetic participants, and
concluded that isocaloric or hypercaloric fructose impairs
hepatic insulin sensitivity but not peripheral or muscle
insulin sensitivity [27]. The included studies were shorter
than 8 weeks except for 3 studies, had lower numbers of
participants, except for 2 studies, and mostly measured
only fasting glucose and insulin. Our results from a 12
weeks fructose intervention in a rather large study popu-
lation are in agreement with the results from the meta-
analysis regarding fasting insulin and HOMA-IR, and
extend the findings to glycemic control and incretin re-
sponses in 4 h OGTT.
The concentration curves for glucose, insulin, GLP-1 and
GIP before and after the intervention are almost super-
imposable (Fig. 1), and consistent with a stable glycemia
also confirmed by calculation of Matsuda and Insulino-
genic indexes. Whether previous findings of deleterious
effects of fructose on insulin sensitivity are due to direct
metabolic effects of fructose itself or a result of increased
energy intake and weight gain remains unanswered. We
have previously reported a defective GLP-1 response in
acquired obesity with liver fat accumulation in young
twins [16]. In contrast, in our current study population, the
overall weight increase was minor, less than 1 kg, but even
when the data were analyzed according to the weight
change during the intervention, we did not find that
weight gain was associated with impaired glycemic con-
trol or incretin responses. Thus, results from studies con-
ducted in free-living conditions may be modulated by
metabolic adaptions to nutrient and caloric intake [28,29].
We observed a range of liver fat changes during the
fructose intervention, although the average absolute in-
crease was only 0.6 percentage points, from 6.9% to 7.5%but a clear increase in postprandial TG AUC and AUIC.
Therefore, we analyzed more closely if liver fat gain during
fructose is a key determinant of abnormal glucose and
lipid metabolism. However, when data were analyzed ac-
cording to changes in liver fat, even the group with the
greatest increase (fat from 8.7% to 11.3%) had no changes in
glucose, insulin or GLP-1 responses during OGTT, with only
marginally significant increases in GIP AUC despite the
worse cardiometabolic profile. The postprandial incretin
responses after the mixed meal were also not related to
changes in liver fat, although the group with increased
liver fat did have a significant increase in TG AUC response.
This may indicate a disconnect between pathways of lipid
and glucose metabolism. The concept of pathway-selective
insulin resistance and responsiveness [30] is consistent
with the results in our population.
We have previously shown that in obese males, GLP-1,
GLP-2 and GIP responses to a mixed meal test are greater
than following an OGTT. However, the contribution of these
hormones to the variance in postprandial TG was minor
[31]. This also is in concordance with our present results
showing that incretin responses do not correlate signifi-
cantly to impairment of lipid metabolism in obese non-
diabetic males and that fructose intervention leading to
increased TG response does not have any modulating effect
on gut incretins during a mixed meal. We conclude that in
these subjects, fructose consumption has little effect on the
gut incretinepancreas pathway or glucose tolerance.
Our study has some strengths and limitations. The time
frame of 12 weeks is longer than in earlier acute or short-
term mechanistic studies [27]. A longer intervention trial
assessing insulin sensitivity with simple measurements in
young adults [32] did not find differences between the
effects of glucose and fructose. With respect to the findings
that changes in the incretin system are early signs of
altered glucose and insulin [15,16], we assume that
changes in gutepancreas axis would be detectable at the
same time when changes in lipid metabolism are seen.
Taken into account that our intervention period is sub-
stantially shorter than follow-up in previous epidemio-
logic studies that demonstrate impaired glucose tolerance
and risk for diabetes with fructose consumption, our re-
sults may not be extrapolated to habitual and life-long use
of excess fructose. Other limitations include lack of mea-
surement of incretin-induced insulin secretion, lack of
control group and standardized background diet, use
liquid fructose beverage rather than naturally occurring
sucrose and no measure of the absorption of fructose.
However, our in our study the amount of fructose and the
way it was served were chosen to mimic a behavior which
is prevalent in Western societies [29].
In summary, our data show that 75 g daily fructose
from SSBs for 12 weeks does not impair gut incretin
response or glucose tolerance in obese males, even in the
presence of moderate weight- or liver fat gain. Based on
our results, the impairment of hepatic lipid handling
and dyslipidemia in non-diabetic obese men due to fruc-
tose consumption may represent an early metabolic
dysfunction in the metabolism of fructose. Our results
Fructose intervention and incretins 541show that these early adverse changes are not linked to
worsening of glucose tolerance or dysregulation of gut
incretins in subjects in high risk for diabetes, at least
within the dose and time frame studied here.Sources of funding
This paper was supported by grants from Helsinki Uni-
versity Central Hospital EVO-funds, Academy of Finland
(grants 266286 and 272376), European Foundation for the
Study of Diabetes, Sigrid Juselius Foundation, Yrjö Jahns-
son Foundation, Juho Vainio Foundation, Foundation
Leducq France, Swedish Research Council, Swedish Heart
Lung Foundation, Diabetes Research Wellness Foundation,
Sahlgrenska University Hospital ALF grant, Swedish Dia-
betes Foundation, the NovoNordisk Foundation, and the
EU Project RESOLVE.Disclosures
M.R.T. from Sanofi-Aventis, Lilly, Merck Sharp & Dohme,
Kowa, Novartis, Novo Nordisk, and AstraZeneca; J.B. from
AstraZeneca, Sanofi-Aventis and Merck Sharp & Dome;
C.F.D. from Boehringer Ingelheim, Lilly, MSD and Novo
Nordisk; K.H.P. from Merck/MSD, Novo Nordisk, and
AstraZeneca; and B.E. from Novo Nordisk, Sanofi, Eli Lilly,
MSD and Boehringer Ingelheim.Conflict of interest
None.
Acknowledgments
We are grateful to Hannele Hilden, Helinä Perttunen-Nio,
Elisa Koivisto, Sylvain Pouliot, Elin Stenfeldt, Eva Hedman-
Sabler and Sofie Pilgaard for excellent laboratory work and
patient care.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.numecd.2017.03.003.
References
[1] Malik VS, Hu FB. Fructose and cardiometabolic health: what the
evidence from sugar-sweetened beverages tells us. J Am Coll
Cardiol 2015;66(14):1615e24.
[2] Bray GA. How bad is fructose? Am J Clin Nutr 2007;86(4):895e6.
[3] Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose,
high-fructose corn syrup, sucrose, and nonalcoholic fatty liver
disease or indexes of liver health: a systematic review and meta-
analysis. Am J Clin Nutr 2014;100(3):833e49.
[4] Sievenpiper JL, de Souza RJ, Cozma AI, Chiavaroli L, Ha V,
Mirrahimi A. Fructose vs. glucose and metabolism: do the meta-
bolic differences matter? Curr Opin Lipidol 2014;25(1):8e19.
[5] Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV,
et al. A dose-response study of consuming high-fructose corn
syrup-sweetened beverages on lipid/lipoprotein risk factors forcardiovascular disease in young adults. Am J Clin Nutr 2015;
101(6):1144e54.
[6] Johnston RD, Stephenson MC, Crossland H, Cordon SM, Palcidi E,
Cox EF, et al. No difference between high-fructose and high-
glucose diets on liver triacylglycerol or biochemistry in healthy
overweight men. Gastroenterology 2013;145(5):1016e25. e2.
[7] Ngo Sock ET, Le KA, Ith M, Kreis R, Boesch C, Tappy L. Effects of a
short-term overfeeding with fructose or glucose in healthy young
males. Br J Nutr 2010;103(7):939e43.
[8] Silbernagel G, Machann J, Unmuth S, Schick F, Stefan N, Häring HU,
et al. Effects of 4-week very-high-fructose/glucose diets on insulin
sensitivity, visceral fat and intrahepatic lipids: an exploratory trial.
Br J Nutr 2011;106(1):79e86.
[9] Maersk M, Belza A, Stodkilde-Jorgensen H, Ringgaard S,
Chabanova E, Thomsen H, et al. Sucrose-sweetened beverages in-
crease fat storage in the liver, muscle, and visceral fat depot: a 6-mo
randomized intervention study. Am J Clin Nutr 2012;95(2):283e9.
[10] Bravo S, Lowndes J, Sinnett S, Yu Z, Rippe J. Consumption of su-
crose and high-fructose corn syrup does not increase liver fat or
ectopic fat deposition in muscles. Appl Physiol Nutr Metab 2013;
38(6):681e8.
[11] Lecoultre V, Egli L, Carrel G, Theytaz F, Kreis R, Schneiter P, et al.
Effects of fructose and glucose overfeeding on hepatic insulin
sensitivity and intrahepatic lipids in healthy humans. Obesity
(Silver Spring) 2013;21(4):782e5.
[12] Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA,
Graham JL, et al. Consuming fructose-sweetened, not glucose-
sweetened, beverages increases visceral adiposity and lipids and
decreases insulin sensitivity in overweight/obese humans. J Clin
Investig 2009;119(5):1322e34.
[13] Aeberli I, Hochuli M, Gerber PA, Sze L, Murer SB, Tappy L, et al.
Moderate amounts of fructose consumption impair insulin
sensitivity in healthy young men: a randomized controlled trial.
Diabetes Care 2013;36(1):150e6.
[14] Meier JJ. GLP-1 receptor agonists for individualized treatment of
type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8(12):728e42.
[15] Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB. Gut incretin hor-
mones in identical twins discordant for non-insulin-dependent
diabetes mellitus (NIDDM)eevidence for decreased glucagon-like
peptide 1 secretion during oral glucose ingestion in NIDDM
twins. Eur J Endocrinol 1996;135(4):425e32.
[16] Matikainen N, Bogl LH, Hakkarainen A, Lundbom J, Lundbom N,
Kaprio J, et al. GLP-1 responses are heritable and blunted in ac-
quired obesity with high liver fat and insulin resistance. Diabetes
Care 2014;37(1):242e51.
[17] Kuhre RE, Gribble FM, Hartmann B, Reimann F, Windeløv JA,
Rehfeld JF, et al. Fructose stimulates GLP-1 but not GIP secretion in
mice, rats, and humans. Am J Physiol Gastrointest Liver Physiol
2014;306(7):G622e30.
[18] Wolnerhanssen BK, Meyer-Gerspach AC, Schmidt A, Zimak N,
Peterli R, Beglinger C, et al. Dissociable behavioral, physiological
and neural effects of acute glucose and fructose ingestion: a pilot
study. PLoS One 2015;10(6):e0130280.
[19] Vozzo R, Baker B, Wittert GA, Wishart JM, Morris H, Horowitz M,
et al. Glycemic, hormone, and appetite responses to mono-
saccharide ingestion in patients with type 2 diabetes. Metabolism
2002;51(8):949e57.
[20] Lundbom J, Hakkarainen A, Soderlund S, Westerbacka J,
Lundbom N, Taskinen MR. Long-TE 1HMRS suggests that liver fat
is more saturated than subcutaneous and visceral fat. NMR Bio-
med 2011;24(3):238e45.
[21] Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP
and GLP-1. Best Pract Res Clin Endocrinol Metab 2009;23(4):
425e32.
[22] Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G, Mari A, et al.
Incretin hormone and insulin responses to oral versus intravenous
lipid administration in humans. J Clin Endocrinol Metab 2011;
96(8):2519e24.
[23] Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and
plasma concentrations of amidated and glycine-extended
glucagon-like peptide I in humans. Diabetes 1994;43(4):535e9.
[24] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC. Homeostasis model assessment: insulin resistance and
beta-cell function from fasting plasma glucose and insulin con-
centrations in man. Diabetologia 1985;28(7):412e9.
542 N. Matikainen et al.[25] Romaguera D, Norat T, Wark PA, Vergnaud AC, Schulze MB, van
Woudenbergh GJ, et al., for the InterAct Consortium. Consumption
of sweet beverages and type 2 diabetes incidence in European
adults: results from EPIC-InterAct. Diabetologia 2013;56:1520e30.
[26] Kelishadi R, Mansourian M, Heidari-Beni M. Association of fruc-
tose consumption and components of metabolic syndrome in
human studies: a systematic review and meta-analysis. Nutrition
2014;30:503e10.
[27] ter Horst KW, Schene MR, Holman R, Romijn JA, Serlie MJ. Effect of
fructose consumption on insulin sensitivity in nondiabetic subjects:
a systematic review and meta-analysis of diet-intervention trials.
Am J Clin Nutr 2016;104(6):1562e76.
[28] Augustin LS, Kendall CW, Jenkins DJ, Willett WC, Astrup A,
Barclay AW, et al. Glycemic index, glycemic load and glycemic
response: an International Scientific Consensus Summit from theInternational Carbohydrate Quality Consortium (ICQC). Nutr Metab
Cardiovasc Dis 2015;25(9):795e815.
[29] Laughlin MR, Bantle JP, Havel PJ, Parks E, Klurfeld DM, Teff K, et al.
Clinical research strategies for fructose metabolism. Adv Nutr
2014;5:248e59.
[30] Williams KJ, Wu X. Imbalanced insulin action in chronic over
nutrition: clinical harm, molecular mechanisms, and a way for-
ward. Atherosclerosis 2016;247:225e82.
[31] Matikainen N, Bjornson E, Soderlund S, Borén C, Eliasson B,
Pietiläinen KH, et al. Minor contribution of endogenous GLP-1 and
GLP-2 to postprandial lipemia in obese men. PLoS One 2016;11(1):
e0145890.
[32] Huttunen JK, Mäkinen KK, Scheinin A. Turku sugar studies XI Ef-
fects of sucrose, fructose and xylitol diets on glucose, lipid and
urate metabolism. Acta Odontol Scand 1976;34(6):345e51.
